Overactive gene associated with more aggressive forms of myeloma
Institute of Cancer Research News Oct 11, 2017
A gene which is overactive in some cases of myeloma has been linked, for the first time, with more aggressive forms of the disease.
Scientists at The Institute of Cancer Research, London, studied data from nearly 1,500 patients with myeloma, which showed that people with high EZH2 expression levels did not live as long and were less likely to continue to respond to treatment, compared with patients whose expression levels were lower.
They also found that blocking the activity of EZH2 in myeloma tumour samples caused changes to the expression of cell cycle control genes, reducing cell division and leading to cell death.
The findings suggest EZH2 plays a key role in the most lethal forms of myeloma, and that targeting the gene could be an effective treatment for the disease when other therapies do not work.
The study was published in the Blood Cancer Journal.
Mutations in the EZH2 gene are found in a range of cancers. Whilst this is not the case in myeloma there is evidence that EZH2 still plays a role in this disease, where changes to gene expression levels are associated with tumour development.
High expression levels of EZH2 in myeloma were associated with shorter survival times on average compared with patients who displayed lower expression levels, regardless of the treatment patients received.
The researchers used two different small-molecule compounds to inhibit EZH2 in myeloma cells, donated by relapsing patients treated at The Royal Marsden, and they saw that both reduced cell viability.
Inhibiting EZH2 caused genes that control the cell division cycle to be upregulated in myeloma, which stopped cell division and led to cell death. First author Dr Charlotte Pawlyn, NIHR Clinical Lecturer at the ICR and Haematologist at The Royal Marsden Hospital, said: ÂMyeloma treatments over the past couple of decades have improved outcomes for many patients with the disease but they have not been very effective for patients with the most aggressive forms of myeloma.
ÂWe have shown for the first time that EZH2 overexpression is associated with worse outcomes for patients with myeloma. Our study demonstrates that EZH2 inhibition may be an effective therapeutic strategy for these patients, potentially even for those with high-risk disease.Â
Go to Original
Scientists at The Institute of Cancer Research, London, studied data from nearly 1,500 patients with myeloma, which showed that people with high EZH2 expression levels did not live as long and were less likely to continue to respond to treatment, compared with patients whose expression levels were lower.
They also found that blocking the activity of EZH2 in myeloma tumour samples caused changes to the expression of cell cycle control genes, reducing cell division and leading to cell death.
The findings suggest EZH2 plays a key role in the most lethal forms of myeloma, and that targeting the gene could be an effective treatment for the disease when other therapies do not work.
The study was published in the Blood Cancer Journal.
Mutations in the EZH2 gene are found in a range of cancers. Whilst this is not the case in myeloma there is evidence that EZH2 still plays a role in this disease, where changes to gene expression levels are associated with tumour development.
High expression levels of EZH2 in myeloma were associated with shorter survival times on average compared with patients who displayed lower expression levels, regardless of the treatment patients received.
The researchers used two different small-molecule compounds to inhibit EZH2 in myeloma cells, donated by relapsing patients treated at The Royal Marsden, and they saw that both reduced cell viability.
Inhibiting EZH2 caused genes that control the cell division cycle to be upregulated in myeloma, which stopped cell division and led to cell death. First author Dr Charlotte Pawlyn, NIHR Clinical Lecturer at the ICR and Haematologist at The Royal Marsden Hospital, said: ÂMyeloma treatments over the past couple of decades have improved outcomes for many patients with the disease but they have not been very effective for patients with the most aggressive forms of myeloma.
ÂWe have shown for the first time that EZH2 overexpression is associated with worse outcomes for patients with myeloma. Our study demonstrates that EZH2 inhibition may be an effective therapeutic strategy for these patients, potentially even for those with high-risk disease.Â
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
